Titlebook: Drugs Targeting B-Cells in Autoimmune Diseases; Xavier Bosch,Manuel Ramos-Casals,Munther A Khamash Book 2014 Springer Basel 2014 Cryoglobu

暗指

Cupidity

Targeting B Cells in Neurological Autoimmune Diseases,the activation-dependent release of cytokines and the mutual activation of T cells, B-cell-directed therapy has emerged as a promising tool in the therapeutic strategies of a range of autoimmune neurological diseases, such as multiple sclerosis (MS), neuromyelitis optica, autoimmune encephalitis, ch

火車車輪

Targeting B Cells in Other Systemic Autoimmune Diseases,ditions, evidence on the use of these therapies is restricted to rituximab and it mainly relies on individual case reports or short series. In general, the underlying pathophysiology of the disease and/or the successful use of biological agents with a different mechanism of action seem to justify th

狂怒

ABOUT

The Future Potential of Biosimilars Targeting B-Cells,pire, leaving open the potential for development and regulatory approval of 1 or more “similar” versions of these biologic therapies, termed biosimilars in Europe (BS)—the term that will be used in this chapter—subsequent entry biologics in Canada, or follow-on-biologics in the USA. The development

Exposition

Natural Resource Management and Policyand for therapeutic uses. The initial drive to specifically target B cells was part of the effort to develop more effective and safer therapeutic agents to treat B-cell malignancies. Anti-idiotype antibodies were effective but a different antibody needed to be developed for each patient, contributin

right-atrium

Water Development and Poverty Reductionmune disease. The last decade has witnessed substantial growth in the number of therapeutic agents that target B cells themselves, or molecules key to B cell survival or function. In order to understand, develop, and eventually predict the outcomes of B cell targeted therapies, a thorough understati

Mediocre

Ryan Hill,Yemi Katerere,Tabeth Matiza-Chiutanoclonal antibody rituximab for the treatment of B cell malignancies and reassurance about the overall safety of B cell depletion, the field of anti-B cell therapies has expanded over the last decade to the treatment of multiple autoimmune diseases. Moreover, growing knowledge of the biology of B ce

iodides

?. H. Olcay ünver,Rajiv K. Gupta disease have led to a growing evidence of the importance of B-cells in the origins of the disease. Two main therapeutic approaches targeting B-cells have emerged: one directed against B-cell specific molecules and the other directed against B-cell survival factors. We will discuss below the differe

fulcrum